Identification of long noncoding RNA NEAT1 as a key gene involved in the extramedullary disease of multiple myeloma by bioinformatics analysis

References

• Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012 Nov;97(11):1761–1767. doi:10.3324/haematol.2012.065698.
   PubMed Web of Science ®Google Scholar
• Besse L, Sedlarikova L, Greslikova H, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016 Jul;97(1):93–100. doi:10.1111/ejh.12688.
   PubMed Web of Science ®Google Scholar
• Cagnetta A, Adamia S, Acharya C, et al. Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. Leuk Res. 2014 Jun;38(6):649–659. doi:10.1016/j.leukres.2014.03.006.
   PubMed Web of Science ®Google Scholar
• Ilyas AM, Ahmad S, Faheem M, et al. Next generation sequencing of acute myeloid leukemia: influencing prognosis. BMC Genomics. 2015;16(Suppl 1):S5. doi:10.1186/1471-2164-16-S1-S5.
   PubMed Web of Science ®Google Scholar
• Garding A, Bhattacharya N, Claus R, et al. Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB. PLoS Genet. 2013 Apr;9(4):e1003373. doi:10.1371/journal.pgen.1003373.
   PubMed Web of Science ®Google Scholar
• Carrasco-Leon A, Ezponda T, Meydan C, et al. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. Leukemia. 2021 May;35(5):1438–1450. doi:10.1038/s41375-021-01147-y.
   PubMed Web of Science ®Google Scholar
• Handa H, Honma K, Oda T, et al. Long noncoding RNA PVT1 Is regulated by bromodomain protein BRD4 in multiple myeloma and Is associated with disease progression. Int J Mol Sci. 2020 Sep 27;21(19). doi:10.3390/ijms21197121.
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT. Haematologica. 2018 May;103(5):890–897. doi:10.3324/haematol.2017.178434.
   PubMed Web of Science ®Google Scholar
• Ryu D, Kim SJ, Hong Y, et al. Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion. Clin Cancer Res. 2020 Feb 15;26(4):935–944. doi:10.1158/1078-0432.CCR-19-0694.
   PubMed Web of Science ®Google Scholar
• Taiana E, Favasuli V, Ronchetti D, et al. Long noncoding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia. 2020 Jan;34(1):234–244. doi:10.1038/s41375-019-0542-5.
   PubMed Web of Science ®Google Scholar
• Zhou X, Flüchter P, Nickel K, et al. Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease. Cancers. 2020 Apr 23;12(4). doi:10.3390/cancers12041035.
   Web of Science ®Google Scholar
• Bladé J, Fernández de Larrea C, Rosiñol L. Extramedullary disease in multiple myeloma in the era of novel agents. Br J Haematol. 2015 Jun;169(6):763–765. doi:10.1111/bjh.13384.
   PubMed Web of Science ®Google Scholar
• Mangiacavalli S, Pompa A, Ferretti V, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017 Jan;96(1):73–80. doi:10.1007/s00277-016-2847-z.
   PubMed Web of Science ®Google Scholar
• West JA, Davis CP, Sunwoo H, et al. The long noncoding RNAs NEAT1 and MALAT1 bind active chromatin sites. Mol Cell. 2014 Sep 4;55(5):791–802. doi:10.1016/j.molcel.2014.07.012.
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Sboner A, Nair SS, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014 Nov 21;5:5383. doi:10.1038/ncomms6383.
   PubMed Web of Science ®Google Scholar
• Geng W, Guo X, Zhang L, et al. Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/β-catenin signaling pathway. Biomed Pharmacother. 2018 Nov;107:484–494. doi:10.1016/j.biopha.2018.08.003.
   PubMed Web of Science ®Google Scholar
• Xu H, Li J, Zhou ZG. NEAT1 promotes cell proliferation in multiple myeloma by activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6403–6411. doi:10.26355/eurrev_201810_16053.
   PubMed Web of Science ®Google Scholar
• Rostami M, Kharajo RS, Parsa-Kondelaji M, et al. Altered expression of NEAT1 variants and P53, PTEN, and BCL-2 genes in patients with acute myeloid leukemia. Leuk Res. 2022 Apr;115:106807. doi:10.1016/j.leukres.2022.106807.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24;471(7339):467–472. doi:10.1038/nature09837.
   PubMed Web of Science ®Google Scholar
• Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012 Aug 2;120(5):1060–1066. doi:10.1182/blood-2012-01-405977.
   PubMed Web of Science ®Google Scholar
• Blume CJ, Hotz-Wagenblatt A, Hüllein J, et al. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 2015 Oct;29(10):2015–2023. doi:10.1038/leu.2015.119.
   PubMed Web of Science ®Google Scholar
• Wang J, Li H, Wang Y, et al. MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28. Oncotarget. 2016 Oct 25;7(43):70194–70210. doi:10.18632/oncotarget.12169.
   PubMedGoogle Scholar
• Zhang J, Wang P, Cui Y. Long noncoding RNA NEAT1 inhibits the acetylation of PTEN through the miR-524-5p /HDAC1 axis to promote the proliferation and invasion of laryngeal cancer cells. Aging. 2021 Nov 27;13(22):24850–24865. doi:10.18632/aging.203719.
   PubMedGoogle Scholar
• Dong P, Xiong Y, Yue J, et al. Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment: advances and challenges. Cancers. 2019 Feb 16;11(2).doi:10.3390/cancers11020234.
   Web of Science ®Google Scholar
• Li A, Qiu M, Zhou H, et al. PTEN,Insulin resistance and cancer. Curr Pharm Des. 2017;23(25):3667–3676. doi:10.2174/1381612823666170704124611.
   PubMed Web of Science ®Google Scholar
• Chu EC, Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit. 2004;10(10):235–241. doi:10.1051/medsci/20042010939.
   Web of Science ®Google Scholar
• Alvarez-Garcia V, Tawil Y, Wise HM, et al. Mechanisms of PTEN loss in cancer: it's all about diversity. Semin Cancer Biol. 2019;59:66–79. doi:10.1016/j.semcancer.
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006 Mar;6(3):184–192. doi:10.1038/nrc1819.
   PubMed Web of Science ®Google Scholar
• Taiana E, Ronchetti D, Favasuli V, et al. Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica. 2019 Feb;104(2):e72–e76. doi:10.3324/haematol.2018.201301.
   PubMed Web of Science ®Google Scholar